Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07625215 · ClinicalTrials.gov registry record · Phase 2
A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation
A Phase 2 study, sponsored by Bayer.
- Not yet
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT07625215: Clinical Trial Phase 2 study, sponsored by Bayer.
NCT07625215 is a Phase 2 study that has not yet begun recruiting, run by Bayer. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07625215, a Phase 2 study, has not yet begun recruiting, sponsored by Bayer.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called electrical cardioversion. Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In this study, each participant will get a single intravenous (IV) infusion of either BAY 3670549 or a placebo. Participants will then be observed to see whether the heart rhythm returns to a normal rhythm. If it does not, electrical cardioversion can still be performed as planned. The study will look at how many participants return from AF to a normal rhythm, without needing electrical cardioversion and how long it takes. It will also show how many participants experience medical problems after treatment and how BAY 3670549 move into, through and out of the participants' body. The total duration of the study for an individual participant may be up two months. The findings from this study may contribute to the development of a new treatment option for people with AF.
Primary Outcome
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care;
Interventions
- OTHER Placebo
- DRUG BAY 3670549
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2026-07-17 |
| Est. Completion | 2030-05-16 |
| Phase | Phase 2 |
What is known before NCT07625215 opens enrollment
NCT07625215 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07625215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07625215 about?
NCT07625215 is a clinical study titled "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation". The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called ele...
What is the current status of trial NCT07625215?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2026-07-17. Estimated completion is 2030-05-16.
What interventions are being tested in trial NCT07625215?
The interventions under investigation include: Placebo (OTHER), BAY 3670549 (DRUG).
Who is sponsoring clinical trial NCT07625215?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07625215's enrollment target sits among peer trials
360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI